Efficacy of desvenlafaxine succinate for menopausal hot flashes

Bibliography

• National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 2005;142:1003-13
   PubMedGoogle Scholar
• Daly E, Gray A, Barlow D, et al. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993;307:836-40
   PubMed Web of Science ®Google Scholar
• Freedman RR, Roehrs TA. Effects of REM sleep and ambient temperature on hot flash-induced sleep disturbance. Menopause 2006;13:576-83
   PubMed Web of Science ®Google Scholar
• Ohayon MM. Severe hot flashes are associated with chronic insomnia. Arch Intern Med 2006;166:1262-8
   PubMed Web of Science ®Google Scholar
• Santoro N. Symptoms of menopause: hot flushes. Clin Obstet Gynecol 2008;51(3):539-48
   PubMed Web of Science ®Google Scholar
• Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990;592:52-86
   PubMed Web of Science ®Google Scholar
• Gold E, Colvin A, Avis N, et al. Longitudinal analysis of vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women’s Health Across the Nation (SWAN). Am J Public Health 2006;96(7):1226-35
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77:1207-18
   PubMed Web of Science ®Google Scholar
• Randolph JF Jr, Sowers M, Bondarenko I, et al. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. J Clin Endocrinol Metab 2005;90(11):6106-12
   PubMedGoogle Scholar
• Freedman R. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005;23(2):117-25
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Lenihan JP, McDermott M, et al. Initial 17-beta estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726-31
   PubMed Web of Science ®Google Scholar
• Gold EB, Lasley B, Crawford SL, et al. Relation of daily urinary hormone patterns to vasomotor symptoms in a racially/ethnically diverse sample of midlife women: study of women’s health across the nation. Reprod Sci 2007;14(8):786-97
   Google Scholar
• Ohayon MM. Severe hot flashes are associated with chronic insomnia. Arch Intern Med 2006;166:1262-8
   PubMed Web of Science ®Google Scholar
• Woods NF, Mitchell ES. Sleep symptoms during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women’s Health Study. Sleep 2010;33:539-49
   PubMed Web of Science ®Google Scholar
• Freedman RR, Roehrs TA. Lack of sleep disturbance from menopausal hot flashes. Fertil Steril 2004;82:138-44
   PubMed Web of Science ®Google Scholar
• Kravitz HM, Joffe H. Sleep during the perimenopause: a SWAN story. Obstet Gynecol Clin North Am 2011;38:567-86
   PubMed Web of Science ®Google Scholar
• Freedman RR, Roehrs TA. Effects of REM sleep and ambient temperature on hot flash-induced sleep disturbance. Menopause 2006;13:576-83
   PubMed Web of Science ®Google Scholar
• Hall MH, Okun ML, Sowers M, et al. Sleep is associated with the metabolic syndrome in a multi-ethnic cohort of midlife women: the SWAN Sleep Study. Sleep 2012;35:783-90
   PubMed Web of Science ®Google Scholar
• Bergmans MG, Merkus JM, Corbey RS, et al. Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study. Maturitas 1987;9:227-34
   PubMed Web of Science ®Google Scholar
• Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-71
   PubMed Web of Science ®Google Scholar
• Hammond MG, Hatley L, Talbert LM. A double blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes. J Clin Endocrinol Metab 1984;58:1158-60
   Google Scholar
• Melis GB, Gambacciani M, Cagnacci A, et al. Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women. Obstet Gynecol 1988;72:688-92
   PubMed Web of Science ®Google Scholar
• Parks V, Patat A, Behrle J, et al. Safety, pharmacokinetics (PK) and pharmacodynamics (PD) ofascendIng single doses of desvenlafaxine (DVS-233 SR) In healthy subjects. Clin Pharmacol Ther 2005;77:28
   Google Scholar
• Wyeth Pharmaceuticals Inc. Pristiq ER (desvenlafaxine) medication guide. Philadelphia, PA; 2010. Available from: http://www.pfizerpro.com/content/showlabeling.asp?id=497 [Acessed 6 January 2010]
   Google Scholar
• Behrle JA, Nichols AI, McGrory SB, Raible D. An open-label, randomized, single-dose, dose-proportionality study of oral doses of a sustainedrelease formulation of desvenlafaxine succinate In healthy subjects. Clin Pharmacol Ther 2005;77:82
   Web of Science ®Google Scholar
• Parker VD, Richards LS, Nichols AI, et al. The absolute broavariability of an oral sustained-release formulation of desvenlafaxme succinate in healthy subjects. Clin Pharmacol Ther 2005;77:47
   Google Scholar
• Richards LS, Behrle JA, Nichols AI, et al. An ascending multiple-dose study ofthe safety and pharmacokinetics of a sustained-release formulation of desvenlafaxme succinate in healthy subjects. Clin Pharmacol Ther 2005;77:84
   Web of Science ®Google Scholar
• Nichols AI, Richards LS, Behrle JA, et al. The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. Int J Clin Pharmacol Ther 2011;49:3-13
   PubMed Web of Science ®Google Scholar
• Eap CB, Bertel-Laubscher R, Zullino D, et al. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report. Pharmacopsychiatry 2000;33:112-15
   PubMed Web of Science ®Google Scholar
• Baird-Bellaire S, Patat AA, Fauchoux N, et al. Effects of chronic hepatic impairment on the pharmacokinetics and safety of desvenlafaxine succinate extended release. Clin Pharmacol Ther 2006;79:26
   Google Scholar
• Patat A, Baird-Bellaire S, Behrle J, et al. Lack of clinically relevant effect of pharrnacokmetrc interaction between ketoconazole on desvenlafaxIne- SR pharmacokinetics. Clin Pharmacol Ther 2007;81(Suppl 1):564; Abstract
   Google Scholar
• Speroff L, Gass M, Constantine G, Olivier S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111(1):77-87
   PubMedGoogle Scholar
• Archer DF, Dupont CM, Constantine GD, et al. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009;200(3):238. e1-238. e10
   Google Scholar
• Archer DF, Seidman L, Constantine GD, et al. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200(2):172. e1- 172. e10
   PubMedGoogle Scholar
• Bouchard P, Panay N, de Villiers TJ, et al. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric 2012;15(1):12-20
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Constantine G, Hwang E, et al. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause 2013;20(1):28-37
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Archer DF, Guico-Pabia CJ, et al. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial. Menopause 2013;20(1):38-46
   Google Scholar
• Sun Z, Hao Y, Zhang M. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. Gynecol Obstet Invest 2013;75(4):255-62
   PubMed Web of Science ®Google Scholar
• Cheng RJ, Dupont C, Archer DF, et al. Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms. Climacteric 2013;16(1):17-27
   PubMed Web of Science ®Google Scholar
• Archer DF, Pinkerton JV, Guico-Pabia CJ, et al. Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause. Menopause 2013;20(1):47-56
   Google Scholar
• Gallagher JC, Strzinek RA, Cheng RF, et al. The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause. J Womens Health 2012;21(2):188-98
   Web of Science ®Google Scholar
• MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2001;CD002978
   Google Scholar
• Tella SH, Gallagher JC. Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause. Expert Opin Pharmacother 2013;14(17):2407-20
   PubMed Web of Science ®Google Scholar
• Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003;10:113-32
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-33
   Google Scholar
• Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475-82
   PubMed Web of Science ®Google Scholar
• Freeman EW, Guthrie KA, Caan B. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305(3):267-74
   PubMed Web of Science ®Google Scholar
• Weber L, Thacker HL. Paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women. Womens Health (Lond Engl) 2014;10(2):147-54
   Google Scholar
• Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-83
   PubMed Web of Science ®Google Scholar
• Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013;20(10):1027-35
   PubMed Web of Science ®Google Scholar
• Yadav M, Volkar J. Potential role of gabapentin and extended-release gabapentin in the management of menopausal hot flashes. Int J Gen Med 2013;6:657-64
   PubMedGoogle Scholar
• Loprinzi CL, Qin R, Balcueva EP, et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol 2010;28:641-7
   PubMed Web of Science ®Google Scholar
• Bergmans MG, Merkus JM, Corbey RS, et al. Effect of Bellergal Retard on climacteric complaints:a double-blind, placebo-controlled study. Maturitas 1987;9:227-34
   PubMed Web of Science ®Google Scholar
• Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes:systematic review and meta-analysis. JAMA 2006;295:2057-71
   PubMed Web of Science ®Google Scholar
• Hammond MG, Hatley L, Talbert LM. A double blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes. J Clin Endocrinol Metab 1984;58:1158-60
   Google Scholar
• Melis GB, Gambacciani M, Cagnacci A, et al. Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women. Obstet Gynecol 1988;72:688-92
   PubMed Web of Science ®Google Scholar
• Tham DM, Gardner CD, Haskell WL. Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 1998;83:2223-35
   PubMed Web of Science ®Google Scholar
• Lewis JE, Nickell LA, Thompson LU, et al. A randomized controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause. Menopause 2006;13:631-42
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137:805-13
   PubMed Web of Science ®Google Scholar